Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.

about

Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T.Malignant pleural mesothelioma: some progress, but still a long way from cure.Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors.

P2860

Q48525241-CEEB6112-838F-43EB-BFA1-B28433EF1B9A Q55064382-BAD03C49-E420-4ADB-AD21-168E2DCA8C1B Q55288740-6DA45398-ADB6-4908-A593-B98ACF16BB5C

P2860

Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.

Item

http://www.wikidata.org/entity/Q47377609

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.

@en

type

Item

label

Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.

@en

prefLabel

Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.

@en

P1476

Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies

@en

P2093

Navin K Chintala

http://www.w3.org/2001/XMLSchema#string

Prasad S Adusumilli

http://www.w3.org/2001/XMLSchema#string

Stefan Kiesgen

http://www.w3.org/2001/XMLSchema#string

P2860

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Molecular Mechanisms for cAMP-Mediated Immunoregulation in T cells - Role of Anchored Protein Kinase A Signaling Units

Clinical manufacturing of CAR T cells: foundation of a promising therapy

The urgent need to recover MHC class I in cancers for effective immunotherapy

Prognostic Significance of Mucin Antigen MUC1 in Various Human Epithelial Cancers: A Meta-Analysis

Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors

Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer

Toxicity and management in CAR T-cell therapy

Adoptive immunotherapy for cancer: harnessing the T cell response

P304

16-26

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JTHO.2017.10.001

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Leonardo Chicaybam

P577

2017-10-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29107016

http://www.w3.org/2001/XMLSchema#string

P932

5738277

http://www.w3.org/2001/XMLSchema#string

Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.

about

P2860

P2860

Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932